4 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute LeukemiaHemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute biphenotypic leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, mixed phenotype acute leukemia, neoplasmRecruitingPhase 32026-07-10NCT05327894
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid TumorsALK-positive anaplastic large cell lymphoma, Granuloma, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, T-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, immune system disorder, immunoproliferative disorder, inflammatory myofibroblastic tumor, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasmRecruitingPhase 1 / Phase 22025-12-05NCT04925609
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML PatientsAcute Myeloid Leukemia in ChildrenRecruitingPhase 22025-08-05NCT06262438
CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML PatientsAcute Myeloid Leukemia in ChildrenRecruitingPhase 32025-08-05NCT05994690